Research of serum biomarker for pancreatic or bile duct cancers using peptide analysis

Research of serum biomarker for pancreatic or bile duct cancers using peptide analysis - Research of biomarker for pancreatic or bile duct cancers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040276

Enrollment

200

Registered

2020-05-01

Start date

2020-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer, bile duct cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients diagnosed as pancreatic or bile duct cancers at Toyama University Hospital with written informed consent.

Exclusion criteria

Exclusion criteria: 1 Patients with high risk of complications from blood sampling. 2 Patients who do not or can not give informed consent.

Design outcomes

Primary

Measure	Time frame
Peptide analysis using BLOTCHIP	—

Secondary

Measure	Time frame
1 Pathological diagnosis 2 Imaging diagnosis 3 Clinical stage	—

Countries

Japan

Contacts

Public ContactTajiri Kazuto

University of Toyama Third Department of Inetrnal Medicine

tajikazu@med.u-toyama.ac.jp076-431-7301

Outcome results